rituximab


Also found in: Medical, Wikipedia.

ri·tux·i·mab

 (rĭ-tŭk′sĭ-măb′)
n.
A chimeric monoclonal antibody used to treat certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and refractory rheumatoid arthritis.

[ri-, origin unknown + tu(mor) + -xi- (alteration of chi(meric), influenced by X, Greek letter chi) + m(onoclonal) a(nti)b(ody).]

rituximab

(rɪˈtʌksɪˌmæb)
n
a monoclonal antibody used to treat non-Hodgkin's lymphoma
Translations

rituximab

n rituximab m
Mentioned in ?
References in periodicals archive ?
Key words: Rituximab; Lymphoma, non-Hodgkin--therapy; Lymphoma, follicular; Maintenance chemotherapy; Treatment outcome
iBio (IBIO) announced that it has expanded the scope of its business venture with CC-Pharming by granting it an exclusive, royalty-bearing commercial license to iBio's bio-better rituximab product candidates for the territory of China.
Shanafelt, M.D., from Stanford University in California, and colleagues randomly assigned 529 patients (aged ≤70 years) with previously untreated CLL in a 2:1 ratio to receive either ibrutinib and rituximab for six cycles (after a single cycle of ibrutinib alone) followed by ibrutinib until disease progression (354 patients) or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for six cycles (175 patients).
- The United States Food and Drug Administration has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of adult patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis, US-based pharmaceutical company Pfizer Inc.
Contract notice: framework agreement for the provision of rituximab (atc code l01xc02) intravenously
IBI301, a co-developed biosimilar product candidate of rituximab (MabThera/Rituxan), is expected to offer a high-quality and affordable alternative to patients in China.
The pivotal study, PIX301 was an open-label, randomised, Phase III study comparing Pixuvri monotherapy with physician's choice of treatment in 140 patients with relapsed or refractory aggressive non-Hodgkin lymphoma, 50% of whom had been previously treated with rituximab.
Approval based on Phase 3 AUGMENT study, which showed the combination significantly improved median progression-free survival versus rituximab monotherapy
B cell cross match may remain positive post desensitization due to the effects of Rituximab which itself, is a monoclonal antibody.
Through the decades, rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine (R-CHOP) therapy has dramatically improved the clinical outcome due to the introduction of rituximab.
ORLANDO -- Rituximab is "quickly emerging" as frontline therapy for pemphigus, Carolyn Kushner said at the International Investigative Dermatology meeting.
El tratamiento estandar de las vasculitis asociadas a ANCAS es la combinacion de ciclofosfamida y esteroides con lo que se ha logrado reducir significativamente la mortalidad (3), pese a ello las complicaciones de este regimen inmunosupresor son elevadas y pueden producir alta morbilidad, como infecciones y cancer, sobre todo en los pacientes mas susceptibles como la poblacion anciana; otros regimenes alternativos de tratamiento han surgido en los ultimos anos como el rituximab que ha demostrado iguales tasas de remision que el esquema estandar con menores complicaciones (4, 5).